Michael Rosenblatt, M.D., is a physician, scientist, educator and leader in healthcare. He currently serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA. Appointed in 2016, he is the first person to serve in this role. He was Executive Vice President and Chief Medical Officer for Merck from 2009-2016. Previously he served as Dean of Tufts University School of Medicine. Prior to that, he held the appointments of Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He served as the President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at BIDMC and served as Director of the Harvard-MIT Division of Health Sciences and Technology. Earlier, he was Senior Vice President for Research at Merck Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis. He is the recipient of the Fuller Albright Award for his work on parathyroid hormone, the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. His major research has been in parathyroid hormone-receptor interactions, elucidating the mechanisms by which breast cancer “homes” to bone, and osteoporosis. Dr. Rosenblatt has been an active participant in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius Pharmaceuticals, a women’s health company developing abaloparatide for osteoporosis. He currently is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of the Massachusetts General Hospital and the Brigham and Women’s Hospital. Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.